Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Barclays PLC

Barclays PLC increased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 195.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,245 shares of the company’s stock after purchasing an additional 112,614 shares during the quarter. Barclays PLC owned 0.12% of Compass Therapeutics worth $314,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after buying an additional 19,095 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after purchasing an additional 31,433 shares in the last quarter. Renaissance Technologies LLC boosted its position in Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares during the last quarter. Rhumbline Advisers raised its holdings in Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after acquiring an additional 12,315 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in Compass Therapeutics in the 3rd quarter worth approximately $79,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $2.60 on Monday. Compass Therapeutics, Inc. has a 1-year low of $0.76 and a 1-year high of $2.70. The firm has a market cap of $357.73 million, a PE ratio of -7.03 and a beta of 0.92. The company has a 50-day moving average of $1.62 and a two-hundred day moving average of $1.50.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Sell-side analysts anticipate that Compass Therapeutics, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CMPX has been the subject of several recent research reports. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $5.00 to $4.00 in a report on Friday, November 15th. D. Boral Capital reissued a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.